%0 Journal Article
%9 ACL : Articles dans des revues avec comité de lecture non répertoriées par l'AERES
%A Chippaux, Jean-Philippe
%A Lang, J.
%A Amadi-Eddine, S.
%A Fagot, P.
%A Le Mener, V.
%T Treatment of snake envenomations by a new polyvalent antivenom composed of highly purified F(ab')2 : results of a clinical trial in northern Cameroon
%D 1999
%L fdi:010021757
%G ENG
%J American Journal of Tropical Medicine and Hygiene
%@ 0002-9637
%K SERPENT ; MORSURE ; VENIN ; TRAITEMENT MEDICAL ; ANTICORPS ; ENFANT ; ADULTE ; ESSAI CLINIQUE
%K FAV-AFRICA ; EFFET INDESIRABLE
%K AFRIQUE SUBSAHARIENNE ; CAMEROUN
%N 6
%P 1017-1018
%U https://www.documentation.ird.fr/hor/fdi:010021757
%> https://horizon.documentation.ird.fr/exl-doc/pleins_textes/pleins_textes_7/b_fdi_55-56/010021757.pdf
%V 61
%W Horizon (IRD)
%X A clinical trail was conducted in 2 health centers in northern Cameroon to assess the safety and efficacy of a new polyvalent antivenom composed of higly purified and pasteurized F(ab')2 (FAV-Africa). Forty-six patients with objective signs of envenomation, including 67% with hemorrhage, were included in the study. Each patient received at least 20 ml of FAV-Africa by direct, slow intravenous injection ; 172 10-ml ampules were administered. All patients were clinically cured after treatment. Two patients (4.3%) showed minor immediate adverse events that may have been related to FAV-Africa (induration, light-headedness) ; no other treatment-related adverse event occurred. No patient had serum sickness. This trial confirms the safety of FAV-Africa administered by intravenous injection and its efficacy in the treatment of snake envenomations in sub-Sahara Africa. (Résumé d'auteur)
%$ 050MEDECI